SentiSense
Ctrl+K
Quick tip: Press
to search stocks
G
GILD
Gilead Sciences, Inc.
$144.99
-0.22 (-0.15%)
Summary
Stories
News
Metrics
Fundamentals
Holders
Full institutional holders data is a Pro feature
UpgradeInstitutional Holders
1987
tracked filers
Total Institutional Value
$58.9B
1987 holders tracked
Report Date
Q4 2025
SEC 13F-HR filing
| Holder | Category | Shares | Value | Weight | Change |
|---|---|---|---|---|---|
STATE STREET CORP | Index Fund | 59.1M | $6.6B | -- | -0.2% |
Capital World Investors | Other | 45.2M | $5.0B | -- | -2.4% |
FMR LLC | Other | 42.1M | $4.7B | -- | -2.3% |
DODGE & COX | Mutual Fund | 30.1M | $3.3B | -- | -2.2% |
Capital Research Global Investors | Mutual Fund | 30.0M | $3.3B | -- | -3.5% |
Data source: SEC EDGAR 13F-HR filings
Company Profile
Symbol
GILD
Market Cap
$180.27B
IPO Date
Jan 22, 1992
CEO
--
Employees
17,000
Sector
--
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Country
United States
Exchange
--
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Read MoreSimilar Stocks
ABBV
AbbVie Inc.
$219.68
-2.52%
AMGN
Amgen Inc.
$366.21
-0.43%
BIIB
Biogen Inc.
$181.55
-1.81%
VRTX
Vertex Pharmaceuticals Incorporated
$469.34
-1.84%
BIIB
Biogen Inc.
$181.55
-1.81%